These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The pharmacology of benzodiazepines: comments on terminology and sources of data. Greenblatt DJ Psychopharmacology (Berl); 1995 Mar; 118(2):119; discussion 120-1. PubMed ID: 7617796 [No Abstract] [Full Text] [Related]
24. [The pharmacokinetic characteristics of fenazepam in epileptics]. Maksutova EL; Sariev AK; Zherdev VP; Voronina TA; Zheleznova EV Eksp Klin Farmakol; 1994; 57(2):16-8. PubMed ID: 7911365 [TBL] [Abstract][Full Text] [Related]
25. [Significance of pharmacokinetic findings for the clinical effect of benzodiazepines]. Horowski R; Dorow R Internist (Berl); 1982 Nov; 23(11):632-40. PubMed ID: 6130052 [No Abstract] [Full Text] [Related]
26. Clinical pharmacokinetics of benzodiazipines. Bailey L; Ward M; Musa MN J Clin Pharmacol; 1994 Aug; 34(8):804-11. PubMed ID: 7962667 [No Abstract] [Full Text] [Related]
27. [Comparative evaluation of anticonvulsant and anti-arrhythmic effects of phenazepam, a benzodiazepine receptor agonist]. Voronina TA; Meerson FZ; Mdzinarishvili AL; Abdikaliev NA; Pshennikova MG Biull Eksp Biol Med; 1990 Feb; 109(2):158-61. PubMed ID: 1970937 [TBL] [Abstract][Full Text] [Related]
28. [Effect of a specific benzodiazepine antagonist RO 15-1788 on phenazepam-induced inhibition of the evoked potentials in hippocampal neurons]. Glushankov PG; Skrebitskiĭ VG Biull Eksp Biol Med; 1983 Nov; 96(11):65-7. PubMed ID: 6315108 [TBL] [Abstract][Full Text] [Related]
29. The realities of clonazepam discontinuation. Freeman S Psychiatr Serv; 1997 Jul; 48(7):881-2. PubMed ID: 9219294 [No Abstract] [Full Text] [Related]
30. Determination of benzodiazepines in ante-mortem and post-mortem whole blood by solid-supported liquid-liquid extraction and UPLC-MS/MS. Sauve EN; Langødegård M; Ekeberg D; Øiestad AM J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():177-88. PubMed ID: 22119506 [TBL] [Abstract][Full Text] [Related]
35. The elimination half-life of benzodiazepines and fall risk: two prospective observational studies. de Vries OJ; Peeters G; Elders P; Sonnenberg C; Muller M; Deeg DJ; Lips P Age Ageing; 2013 Nov; 42(6):764-70. PubMed ID: 23900130 [TBL] [Abstract][Full Text] [Related]
36. [Pharmacokinetic evaluation of the tablet dosage forms of gidazepam prepared by various technologies]. Kolyvanov GB Eksp Klin Farmakol; 2004; 67(2):63-6. PubMed ID: 15188766 [TBL] [Abstract][Full Text] [Related]
37. [Therapeutic effect and pharmacokinetics of transdermal phenazepam preparation in patients with different anxiety disorders]. Dorofeeva OA; Siuniakov SA; Zherdev VP; Kolyvanov GB; Litvin AA; Neznamov GG Eksp Klin Farmakol; 2009; 72(2):6-10. PubMed ID: 19441719 [TBL] [Abstract][Full Text] [Related]
38. [Clinical pharmacology of benzodiazepine tranquilizers]. Janicki P; Rewerski W Pol Tyg Lek; 1981 Aug; 36(34):1313-6. PubMed ID: 6121319 [No Abstract] [Full Text] [Related]
39. [Role of GABA-ergic and dopaminergic mechanisms in the withdrawal syndrome after discontinuation of long-term phenazepam administration]. Voronina TA; Garibova TL Biull Eksp Biol Med; 1980 Jul; 89(7):41-3. PubMed ID: 6773598 [TBL] [Abstract][Full Text] [Related]
40. [Factors affecting the metabolism and distribution of phenazepam in subcellular fractions of animal hepatocytes]. Golovenko NIa; Zin'kovskiĭ VG; Zhuk OV; Meteshkin IuV Vopr Med Khim; 1984; 30(4):67-71. PubMed ID: 6506587 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]